Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential.

Sho Sato Takahito Miura Aiko Ogasawara Daisuke Shintani Shogo Yamaguchi Hiroaki Inui Akiko Yoshinaga Masahiko Nishiyama Momomi Tsugane Kosei Hasegawa

Published in: Journal of gynecologic oncology (2024)

Our results showed that YHO-1701 suppressed cell growth in PDCs of OC, accompanied by survivin inhibition, and a decrease in the number of peritoneal metastasis in the mice by YHO-1701, compared with those treated with control. Therefore, YHO-1701 could be a promising candidate agent for treating OC.

Keyphrases

single cell
cell therapy
high fat diet induced
type diabetes
metabolic syndrome
insulin resistance
bone marrow
wild type